Indivior Pharmaceuticals, Inc. · NASDAQ:INDV
Indivior Pharmaceuticals — Q4 2024 Earnings Presentation
22 slides from Indivior Pharmaceuticals's earnings presentation, Feb 20, 2025
Slide 1: FY / Q4 2024 Results
FY / Q4 2024 Results FEBRUARY 20, 2025
Slide 2: Important Cautionary Statement Regarding Forward-looking Statements
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Important Cautionary Statement Regarding Forward-looking Statements This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Indivior Group’s
Slide 3: Mark Crossley, Chief Executive Officer
Mark Crossley Chief Executive Officer FY / Q4 2024 Results | February 20, 2025
Slide 4: Call Agenda
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Call Agenda Overview & Strategic Update………………………………………..........................................................Mark Crossley, CEO Commercial Update…………………………………………………………………………………………………………………………….Richard Simkin, CCO Q4 / FY 2024 Performance & FY 2025 Guidance
Slide 5: FY 2024 Highlights
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 TOTAL NET REVENUE (NR) SUBLOCADE® NR FY 2024 Highlights1 $1,188m $756m +9% +20% OPERATING PROFIT / (LOSS) ADJUSTED OPERATING PROFIT2 ($23m) $312m NM3 +16% EARNINGS PER SHARE ADJUSTED EARNINGS PER SHARE2 ($0.36) $1.66 NM +6% • Delivered top- and bottom-line gr
Slide 6: Executing Against our Strategic Priorities
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Executing Against our Strategic Priorities Grow >$1.5Bn Diversify Revenue • FY 2024 SUBLOCADE NR growth of 20% continues to be • OPVEE: successful fulfillment of BARDA orders; 170 driven by OHS and CJS penetration experience programs underway; OPVEE included
Slide 7: Capital Allocation Framework
FY / Q4 2024 Results | FEBRUARY 20, 2025 Capital Allocation Framework Cash: Existing and Generated Near-term Organic Growth and Business Needs: Capital Allocation • • Maintain flexibility and meet obligations Reinvest in growth (current products) Focus • R&D / Supply Business Development Shareholder
Slide 8: Richard Simkin, Chief Commercial Officer
Richard Simkin Chief Commercial Officer FY / Q4 2024 Results | February 20, 2025
Slide 9: Strong SUBLOCADE Progression
FY / Q4 2024 Results | FEBRUARY 20, 2025 Strong SUBLOCADE Progression SUBLOCADE® Active HCPs SUBLOCADE® Total Patients1 SUBLOCADE® Net Revenue (in Thousands) (in $-Millions) 10,665 170.5 $756 8,768 136.9 $630 6,322 82.5 $408 4,373 49.0 $244 3,263 28.9 $130 2020 2021 2022 2023 2024 2020 2021 2022 202
Slide 10: Reinvesting to Unlock SUBLOCADE Potential
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Reinvesting to Unlock SUBLOCADE Potential Investment Strategies HCPs Near Term Growth Challenges Win with HCPs on efficacy as the #1 treatment factor Patients • Competing LAI Entrant in U.S. ~$50m Amplify patient requests at scale Reallocated Commercial Inves
Slide 11: Positive Long-term Fundamentals for SUBLOCADE Remain Unchanged
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Positive Long-term Fundamentals for SUBLOCADE Remain Unchanged Range of Patient Estimates Across Key Metrics 4.0m1 8.9m2 12.0m3 People misusing opioids in U.S. (Total Addressable Market) 2 3.1m2 2.7m4 OUD patients diagnosed 6.1m2 in U.S. (Service Addressable
Slide 12: OPVEE: Focused on Translating Experience Programs into Adoption
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 OPVEE: Focused on Translating Experience Programs into Adoption BARDA1 Contract • $15m NR delivered in 2024 (including one annual contractual order and one incremental order) • Expect $10m to $15m total NR in 2025 (including one annual contractual order from
Slide 13: Ryan Preblick, Chief Financial Officer
Ryan Preblick Chief Financial Officer FY / Q4 2024 Results | February 20, 2025
Slide 14: Q4 2024 Financial Highlights (IFRS)
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Q4 2024 Financial Highlights (IFRS): OPERATING RESULTS: (REPORTED AND ADJUSTED1) KEY TAKEAWAYS: (VS Q4 2023 UNLESS OTHERWISE INDICATED) $ mil Q4 2024 Q4 2023 Change Net Revenue (NR): $298 $293 2% Total NR growth of 2% (2% at constant FX) U.S. NR 251 249 1% •
Slide 15: FY 2024 Financial Highlights (IFRS)
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 FY 2024 Financial Highlights (IFRS): OPERATING RESULTS: (REPORTED AND ADJUSTED1) KEY TAKEAWAYS: (VS FY 2023 UNLESS OTHERWISE INDICATED) $ mil FY 2024 FY 2023 Change Net Revenue (NR): $1,188 $1,093 9% Total NR growth of 9% (+9% at constant FX) U.S. NR 1,008 91
Slide 16: Cash and Borrowing Position (IFRS)
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Cash and Borrowing Position (IFRS): CASH AND BORROWINGS: KEY TAKEAWAYS: (VS DECEMBER 31, 2023 UNLESS OTHERWISE INDICATED) ($ in mil.) December 31, 2024 December 31, 2023 Cash & investments of $347m1 Cash & Cash Equivalents 319 316 • Net cash flow from operati
Slide 17: FY 2025 Guidance (U.S. GAAP)
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 FY 2025 Guidance1 (U.S. GAAP) GUIDANCE ITEMS: (SEE APPENDIX FOR FY 2024 U.S. GAAP COMPARATIVE ITEMS) TOP-LINE ASSUMPTIONS: Total NR decline of 17% at the mid-point reflects U.S. SUBOXONE Film (11pp of the decline) and PERSERIS discontinuation (3pp of the decl
Slide 18: Appendix
Appendix
Slide 19: Transition from IFRS to U.S. GAAP
FY / Q4 2025 RESULTS | FEBRUARY 20, 2025 Transition from IFRS to U.S. GAAP Reported results for Q4 / FY 2024 (February 20, 2025): • Actual Q4 / FY 2024 results and prior year Q4 / FY 2023 comparisons under IFRS accounting methodology. • Guidance for FY 2025 provided under U.S. GAAP with comparisons
Slide 20: Financial Reconciliations
Reconciliation of gross profit to adjusted gross profit FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 Q4 Q4 FY FY 2024 2023 2024 2023 Financial For the three and twelve months ended December 31 $m $m $m $m Reconciliations1 Gross profit 248 241 930 907 Exceptional items and other adjustments in cost of sa
Slide 21: FY 2024 U.S. GAAP Reconciliations
FY / Q4 2024 RESULTS | FEBRUARY 20, 2025 FY 2024 U.S. GAAP RECONCILIATIONS FY 2024 For the twelve months ended December 31, 2024 $m IFRS Adjusted Gross Profit 990 Difference 7 U.S. GAAP Adjusted Gross Profit 997 FY 2024 For the twelve months ended December 31, 2024 $m IFRS Adjusted Selling, General
Slide 22: Indivior
5 INDIVIOR
Indivior Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix